Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma. Using this technology, biological subgroups of DLBCL can be identified that have unique targets for rational therapeutic intervention. This review summarizes these potential targets, and updates the progress of clinical development of exciting novel agents for the treatment of diffuse large B-cell lymphoma. Based upon these ongoing studies, it is likely that in the near future, we will utilize gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for an individual patient with DLBCL.
transactivator CIITA, which impacts survival in this subtype of DLBCL. (12) In further support of the concept that these subtypes are really different diseases, the activated Bcell lymphomas have inferior prognosis, which appears to be an even more powerful predictor of outcome than the IPI, in patients treated with CHOP-like regimens. (8) Gene expression profiling also provides prognostic information in the rituximab era.
Currently, an intergroup trial coordinated by CALGB is randomizing patients to R-CHOP vs. R-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and has incorporated gene expression analysis to validate outcome differences between germinal center and activated B-cell DLBCL. In an updated analysis from the aforementioned lymphoma/leukemia molecular profiling project, which included tumor biopsies from over two hundred patients with DLBCL treated with R-CHOP, a multivariate model demonstrated the importance of the microenvironment on outcome.(13) The prognostically-favorable "stromal-1" signature reflected extracellular matrix and histiocytic infiltration. The less favorable "stromal-2" signature appears to be an angiogenic switch, in which development of lymphoma is accompanied by angiogenesis, perhaps induced in part by surrounding macrophages. Friedberg DLBCL gene expression profiling a supervised learning prediction method to identify cured patients from patients with fatal or refractory disease. In this series, genes implicated in poor DLBCL outcome (fatal/refractory) included NOR1, PDE4B and PKC-beta, which regulate apoptotic responses to antigen receptor engagement.
Taken together, these gene expression studies have revolutionized the way we think about this most common adult lymphoma. Observed clinical heterogeneity can now be explained by dramatic differences in biology, despite a similar morphological appearance.
These differences not only provide robust prognostic information, but have yielded several important novel targets for therapeutic intervention. (15) The remainder of this review discusses clinical progress of some of these targeted approaches, and looks forward to an era where specific subgroups of patients with DLBCL are approached with rationally targeted therapy.
On the Horizon

Development of novel agents targeting findings from gene expression analysis
Nuclear factor kappa-B: As previously mentioned, constitutive activation of the nuclear 
